Given that tumor microenvironment is tightly associated with tumor progression and therapy [45–49], and ccRCC is a type of classical immune-infiltrated tumor [50–52], we propose that CDCA5-mTOR may also participate tumor immunity and this is deserved to be determined. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.